Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Andrew L. (Larry) Frelinger, PhD
Researcher Associate Director of the Center for Platelet Research Studies
Boston Children’s Hospital
300 Longwood Avenue
Karp Research Building - Room 08213
Boston, Massachusetts, United States
Dr. Frelinger is Assistant Professor of Pediatrics at Harvard Medical School and Associate Director of the Center for Platelet Research studies at Boston Children’s Hospital. Dr. Frelinger also holds a joint appointment at the Dana-Farber Cancer Institute. Dr. Frelinger is currently a co-chairman of the Platelet Physiology Scientific Subcommittee of the Scientific and Standardization Committee (SSC), International Society on Thrombosis and Haemostasis (ISTH). He has authored more than 80 peer-reviewed original research articles and has been an invited speaker at national and international meetings on the topic of platelet biology and antiplatelet agents.
For more than 25 years the focus of Dr. Frelinger’s research has been translational studies, combining basic and clinical research, related to platelets and thrombosis. He discovered novel epitopes whose exposure is modulated by ligand binding (ligand-induced binding sites or LIBS) on the cell adhesion receptor glycoprotein IIb-IIIa (GPIIb-IIIa). His work has focused on investigations of basic platelet biology, development of platelet-related therapeutics, and evaluation of anti-platelet therapy through clinical trials.
His research interests include 1) antiplatelet therapy as a treatment modality for sickle cell disease 2) the effects of thrombopoietin mimetics on platelet activation, 3) novel diadenosine tetraphosphate analogs with dual specificity for platelet P2Y1 and P2Y12 ADP receptors for their potential as anti-platelet drugs, 4) platelet function as a contributor to bleeding in immune thrombocytopenia, 5) platelets as models of neurons, and 6) induced pluripotent stem cell-derived platelets for therapeutic applications.
Representative Publications:
Platelet activation and inhibition in sickle cell disease (pains) study
+myBinderRelated Content
-
Froedtert Hospital, Sickle Cell ClinicSickle cell disease (SCD) is a genetic d...
-
Jerlym S. Porter, PhD, MPHJerlym S. Porter is an Associate Member ...
-
Blood Industry Joins Together During Coronavirus Challengeshttps://www.youtube.com/watch?v=Z3V_DX_A...
-
Building Access to Care in Adult Sickle Cell Disease: Defining Models of Care, Essential Components, and Economic As...Sickle cell disease (SCD) is the most co...
-
Z. Jim Wang, PhDDr. Wang is a professor of pharmacology ...
-
Improving Sickle Cell Transitions of Care Through Health Information TechnologyINTRODUCTION: Transitions between inpati...
-
Patients With Sickle Cell Disease may Have Lower Risk for C. DifficileFindings from a retrospective cohort stu...
